Minimally invasive approach for peritoneal surface malignancies: a surgical dilemma?

The enduring evolution of surgical techniques has led to a wider landscape of treatment approaches, especially for those conditions in which palliative care was the only viable option. Peritoneal carcinomatosis can occur in a variety of malignancies and represents one of these poorly prognostic conditions. The current surgical standard of care for peritoneal surface malignancies (PSM) consists of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) (1).